• AI-10-49: Precision CBFβ-SMMHC Inhibitor for AML Research

  2026-07-03

  AI-10-49 enables targeted, mechanism-based disruption of leukemogenic pathways in acute myeloid leukemia research by selectively antagonizing CBFβ-SMMHC. Its robust experimental performance and validated workflows empower both mechanistic studies and translational investigations, setting a new standard for selective leukemia inhibitor tools.

• VX-702 in Translational Inflammation Models: Mechanistic and

  2026-07-03

  Discover how VX-702, a potent p38α MAPK inhibitor, enables advanced translational research in inflammation and tissue injury. This article uniquely explores mechanistic breakthroughs and practical assay strategies, setting VX-702 apart for precision experimental design.

• Sequential BCL-XL and MCL-1 Inhibition Sensitizes Glioblasto

  2026-07-02

  The referenced study uncovers that glioblastoma (GBM) cells, especially stem-like subtypes, show heightened expression of anti-apoptotic BCL-XL and MCL-1 proteins, rendering them highly susceptible to apoptosis when these proteins are inhibited. Sequential application of BH3-mimetics targeting BCL-XL and MCL-1 leads to robust anti-tumor responses in preclinical models, highlighting a promising therapeutic strategy for overcoming GBM treatment resistance.

• UBR1 and UBR2: Central ER Stress Sensors in Protein Quality

  2026-07-02

  This study identifies UBR1 and UBR2 as key E3 ubiquitin ligases stabilizing protein quality control under ER stress in mammalian cells. The findings clarify a previously obscure layer of ER-associated degradation and have practical implications for research on ER stress, apoptosis, and cancer cell survival.

• Alfuzosin HCl: Innovations in Gastroretentive Drug Delivery

  2026-07-01

  Discover how Alfuzosin HCl, a selective α1 adrenoceptor antagonist, is revolutionizing benign prostatic hyperplasia research through advanced gastroretentive delivery systems. This article provides in-depth scientific insights and practical protocol guidance, setting it apart from conventional overviews.

• Ibotenic Acid as NMDA Receptor Agonist: Models & Workflows

  2026-07-01

  Ibotenic acid, a potent NMDA receptor agonist, is transforming animal modeling of neurodegenerative disorders with its reproducibility and mechanistic specificity. This article details optimized workflows, troubleshooting strategies, and the latest translational insights, positioning APExBIO's ibotenic acid as an essential neuroscience research tool.

• Saquinavir as an HIV Protease Inhibitor: Applied Workflows &

  2026-06-30

  Saquinavir unlocks robust, reproducible HIV protease inhibition workflows, now empowered by biomimetic chromatography for precise permeability modeling. Learn how to optimize experimental protocols and troubleshoot common pitfalls, leveraging APExBIO’s high-purity standard for cross-domain drug research.

• Proteoform-Specific Drug Interactions in Native Cell Signali

  2026-06-30

  This study pioneers the direct analysis of drug-protein interactions at the proteoform level within native lipid bilayers, illuminating how post-translational modifications and alternative splicing drive specificity. The findings reveal distinct off-target binding profiles of PDE5 inhibitors such as sildenafil, offering novel perspectives for precision pharmacology and safer drug development.

• L-NAME Hydrochloride: Precision NOS Inhibition in Vascular M

  2026-06-29

  L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester) is the gold standard for dissecting nitric oxide pathways in cardiovascular and inflammation research. Explore practical workflows, validated protocols, and troubleshooting strategies that maximize assay robustness and translational impact.

• Fludarabine in Translational Oncology: Mechanism to Applicat

  2026-06-29

  Explore how Fludarabine's mechanistic action as a DNA synthesis inhibitor empowers translational oncology research. This article bridges molecular rationale, robust validation, and evolving best practices—providing strategic guidance for researchers advancing leukemia and multiple myeloma models. Drawing on recent workflow advances and clinical context, it highlights how precision use of Fludarabine, available from APExBIO, can maximize scientific impact.

• Translating mRNA Delivery: Dual-Reporter Innovation & Strate

  2026-06-28

  This thought-leadership article explores the mechanistic, technical, and translational advances enabled by EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP). It integrates insights from cutting-edge research on muco-penetrating nanoparticles, strategic guidance for optimizing mRNA delivery and transfection, and the unique value of dual-modality reporters for translational researchers. Anchored in recent literature and competitive benchmarking, the article provides a framework for next-generation assay development, immune evasion strategies, and actionable protocol parameters.

• Exemestane’s Role in Precision Estrogen Modulation Research

  2026-06-27

  Discover how Exemestane, a leading steroidal aromatase inhibitor, is transforming precision research on estrogen biosynthesis inhibition. This article uniquely bridges molecular pharmacology and assay design to empower innovative breast cancer studies.

• Remdesivir (GS-5734) in Antiviral Workflows: Practical Bench

  2026-06-26

  Remdesivir (GS-5734) unlocks high-integrity, reproducible inhibition of RNA viruses in both coronavirus and Ebola research models. This article delivers actionable experimental parameters, workflow optimizations, and troubleshooting strategies to maximize antiviral assay outcomes and data quality.

• AZD2461: Advancing PARP Inhibition and Overcoming Resistance

  2026-06-26

  Discover how AZD2461, a novel PARP inhibitor, is reshaping breast cancer research by integrating mechanistic insight with translational strategy. This article bridges evidence from latest in vitro methodologies and real-world assay optimization, offering actionable guidance for overcoming drug resistance and refining DNA repair pathway studies.

• IGF2BP1–THBS1–TLR4 Axis Drives Macrophage Metabolic Rewiring

  2026-06-25

  This study identifies the m6A reader IGF2BP1 as a key regulator of macrophage glycolysis and fibrotic phenotype in pulmonary fibrosis, acting through stabilization of THBS1 mRNA and interaction with TLR4. These findings illuminate a novel mechanism for macrophage-driven fibrosis and suggest new targets for therapeutic intervention.

443 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page